Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1Suspended 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Other solid neoplasm 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Immune-related Adverse Event 1

Interventions

venetoclax 190Cyclophosphamide 124Azacitidine 112Cytarabine 108fludarabine 92Specimen Handling 75Biopsy 54Daunorubicin 42Methotrexate 40Dexamethasone 37Rituximab 34blinatumomab 32Vincristine 31Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Magnetic Resonance Spectroscopy 27Whole-Body Irradiation 26obinutuzumab 25Idarubicin 25acalabrutinib 23Mycophenolic Acid 23Prednisone 22Melphalan 21Busulfan 21gilteritinib 19Stem Cell Transplantation 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Antineoplastic Agents × Other hematologic neoplasm × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡